Essential Role of Aldehyde Dehydrogenase 1A3 for the Maintenance of Non–Small Cell Lung Cancer Stem Cells Is Associated with the STAT3 Pathway

Purpose: Lung cancer stem cells (CSC) with elevated aldehyde dehydrogenase (ALDH) activity are self-renewing, clonogenic, and tumorigenic. The purpose of our study is to elucidate the mechanisms by which lung CSCs are regulated. Experimental Design: A genome-wide gene expression analysis was performed to identify genes differentially expressed in the ALDH+ versus ALDH− cells. RT-PCR, Western blot analysis, and Aldefluor assay were used to validate identified genes. To explore the function in CSCs, we manipulated their expression followed by colony and tumor formation assays. Results: We identified a subset of genes that were differentially expressed in common in ALDH+ cells, among which ALDH1A3 was the most upregulated gene in ALDH+ versus ALDH− cells. shRNA-mediated knockdown of ALDH1A3 in non–small cell lung cancer (NSCLC) resulted in a dramatic reduction in ALDH activity, clonogenicity, and tumorigenicity, indicating that ALDH1A3 is required for tumorigenic properties. In contrast, overexpression of ALDH1A3 by itself it was not sufficient to increase tumorigenicity. The ALDH+ cells also expressed more activated STAT3 than ALDH− cells. Inhibition of STAT3 or its activator EZH2 genetically or pharmacologically diminished the level of ALDH+ cells and clonogenicity. Unexpectedly, ALDH1A3 was highly expressed in female, never smokers, well-differentiated tumors, or adenocarcinoma. ALDH1A3 low expression was associated with poor overall survival. Conclusions: Our data show that ALDH1A3 is the predominant ALDH isozyme responsible for ALDH activity and tumorigenicity in most NSCLCs, and that inhibiting either ALDH1A3 or the STAT3 pathway are potential therapeutic strategies to eliminate the ALDH+ subpopulation in NSCLCs. Clin Cancer Res; 20(15); 4154–66. ©2014 AACR.

[1]  M. Schweder,et al.  Overexpression of the human aldehyde dehydrogenase class I results in increased resistance to 4-hydroperoxycyclophosphamide. , 1996, Cancer gene therapy.

[2]  J. Shih,et al.  ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors. , 2013, Cancer letters.

[3]  C. Bloomfield,et al.  All-trans-Retinoic Acid in Acute Promyelocytic Leukemia , 2000 .

[4]  F. Bertucci,et al.  Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. , 2009, Cancer research.

[5]  Anna E. Lokshin,et al.  Drug-Selected Human Lung Cancer Stem Cells: Cytokine Network, Tumorigenic and Metastatic Properties , 2008, PloS one.

[6]  P. Andrews,et al.  Retinoic acid directs neuronal differentiation of human pluripotent stem cell lines in a non-cell-autonomous manner. , 2010, Differentiation; research in biological diversity.

[7]  F. Hamdy,et al.  High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. , 2010, Cancer research.

[8]  Lakshmaiah Sreerama,et al.  Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study , 2002, Cancer Chemotherapy and Pharmacology.

[9]  Surendra Singh,et al.  Aldehyde dehydrogenase 1B1 (ALDH1B1) is a potential biomarker for human colon cancer. , 2011, Biochemical and biophysical research communications.

[10]  D. Nam,et al.  Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. , 2013, Cancer cell.

[11]  J. Whitesides,et al.  Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[12]  P. Adamson,et al.  Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  C. Brocker,et al.  Non-P 450 aldehyde oxidizing enzymes : the aldehyde dehydrogenase superfamily , 2009 .

[14]  P. Russell,et al.  The prognostic significance of aldehyde dehydrogenase 1A1 (ALDH1A1) and CD133 expression in early stage non-small cell lung cancer , 2013, Thorax.

[15]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[16]  A. Allan,et al.  The Role of Human Aldehyde Dehydrogenase in Normal and Cancer Stem Cells , 2011, Stem Cell Reviews and Reports.

[17]  D. Mohuczy,et al.  Retinoic Acid Down-Regulates Aldehyde Dehydrogenase and Increases Cytotoxicity of 4-Hydroperoxycyclophosphamide and Acetaldehyde , 2005, Journal of Pharmacology and Experimental Therapeutics.

[18]  Li Lin,et al.  STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. , 2011, Cancer research.

[19]  Feng Jiang,et al.  Aldehyde Dehydrogenase 1 Is a Tumor Stem Cell-Associated Marker in Lung Cancer , 2009, Molecular Cancer Research.

[20]  J. Visvader,et al.  Cancer stem cells in solid tumours: accumulating evidence and unresolved questions , 2008, Nature Reviews Cancer.

[21]  I. Herr,et al.  CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non‐small cell lung cancer patients , 2009, International journal of cancer.

[22]  Laura A. Sullivan,et al.  Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. , 2010, Cancer research.

[23]  F. Bertucci,et al.  Aldehyde Dehydrogenase 1–Positive Cancer Stem Cells Mediate Metastasis and Poor Clinical Outcome in Inflammatory Breast Cancer , 2009, Clinical Cancer Research.

[24]  N. Maitland,et al.  JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells. , 2013, Cancer research.

[25]  References , 1971 .

[26]  D. Birnbaum,et al.  CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. , 2010, The Journal of clinical investigation.

[27]  P. Marcato,et al.  Aldehyde dehydrogenase: Its role as a cancer stem cell marker comes down to the specific isoform , 2011, Cell cycle.

[28]  H. Baker,et al.  ALDH isozymes downregulation affects cell growth, cell motility and gene expression in lung cancer cells , 2008, Molecular Cancer.

[29]  J. Minna,et al.  Human lung cancer cell lines exhibit resistance to retinoic acid treatment. , 1993, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[30]  A. Cheung,et al.  Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential , 2007, Leukemia.

[31]  Patrick W. Lee,et al.  Aldehyde Dehydrogenase Activity of Breast Cancer Stem Cells Is Primarily Due To Isoform ALDH1A3 and Its Expression Is Predictive of Metastasis , 2011, Stem cells.

[32]  L. Nicholson,et al.  Finding cancer stem cells: are aldehyde dehydrogenases fit for purpose? , 2010, The Journal of pathology.

[33]  F. Gonzalez,et al.  Retinoic acid modulates retinaldehyde dehydrogenase 1 gene expression through the induction of GADD153-C/EBPbeta interaction. , 2009, Biochemical pharmacology.

[34]  R. Ferris,et al.  Targeting ALDHbright Human Carcinoma–Initiating Cells with ALDH1A1-Specific CD8+ T Cells , 2011, Clinical Cancer Research.

[35]  B. Levi,et al.  Aldehyde dehydrogenase 1a1 is dispensable for stem cell function in the mouse hematopoietic and nervous systems. , 2009, Blood.

[36]  M. Clarke,et al.  Stem Cells and Cancer: Two Faces of Eve , 2006, Cell.

[37]  Xiangjiao Meng,et al.  Both CD133+ and CD133− subpopulations of A549 and H446 cells contain cancer‐initiating cells , 2009, Cancer science.

[38]  L. Mariani,et al.  Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment , 2009, Proceedings of the National Academy of Sciences.

[39]  Yang Xie,et al.  Enhanced identification and biological validation of differential gene expression via Illumina whole-genome expression arrays through the use of the model-based background correction methodology , 2008, Nucleic acids research.

[40]  M. McCarter,et al.  ALDH1A Isozymes are Markers of Human Melanoma Stem Cells and Potential Therapeutic Targets , 2012, Stem cells.

[41]  Lakshmaiah Sreerama,et al.  ALDH1A1 and ALDH3A1 expression in lung cancers: correlation with histologic type and potential precursors. , 2008, Lung cancer.

[42]  Stephen Lam,et al.  Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. , 2007, Cancer research.

[43]  J. Visvader,et al.  Cancer stem cells: current status and evolving complexities. , 2012, Cell stem cell.

[44]  J. Moreb,et al.  Heterogeneity of aldehyde dehydrogenase expression in lung cancer cell lines is revealed by Aldefluor flow cytometry‐based assay , 2007, Cytometry. Part B, Clinical cytometry.

[45]  M. Biffoni,et al.  Identification and expansion of the tumorigenic lung cancer stem cell population , 2008, Cell Death and Differentiation.

[46]  G. Duester,et al.  Cytosolic retinoid dehydrogenases govern ubiquitous metabolism of retinol to retinaldehyde followed by tissue-specific metabolism to retinoic acid. , 2003, Chemico-biological interactions.

[47]  F. Bertucci,et al.  Retinoid signaling regulates breast cancer stem cell differentiation , 2009, Cell cycle.